Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ansell Limited (ANN.AX)
Richmond, VIC, AU
Ansell Limited is a global enterprise that conceptualizes, innovates, and produces protective equipment for various industries across numerous regions, including Asia Pacific, Europe, the Middle East, Africa, the Americas, and the Caribbean. The company's operations are divided into two principal divisions: Healthcare and Industrial. The Healthcare division focuses on crafting and distributing products such as surgical, single-use, and examination gloves, alongside specialized cleanroom and sterile gloves and apparel. These offerings cater to a diverse clientele including medical facilities, surgical clinics, dental offices, veterinary practices, emergency services, research laboratories, and pharmaceutical and life science firms. Conversely, the Industrial segment provides hand and chemical protective gear designed for a wide array of demanding applications, from the automotive, chemical, and metal fabrication sectors to machinery, food processing, construction, mining, oil and gas industries, and first responders. Established in 1893 and headquartered in Richmond, Australia, the company was initially known as Pacific Dunlop Limited before rebranding to Ansell Limited in 2002. P. D. Holdings Pty. Ltd. currently operates as a subsidiary of Ansell Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.88% | +6.10% | +5.41% | -14.20% | -25.71% | -20.45% | -11.73% | +3.65% | -32.57% | +44.23% | +85.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+23.7% ★ Q4'25: +33.2% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+18.6% ★ Q4'25: +313.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+5.5% Q4'25: +10.3% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+9.3% Q4'25: +13.6% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+5.2% Q4'25: +16.0% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+12.9% Q4'25: +15.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.10× Q4'25: 1.26× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 11 Rev. Ana. 9 EPS Ana. |
Jun 2027 11 Rev. Ana. 9 EPS Ana. |
Jun 2028 11 Rev. Ana. 7 EPS Ana. |
Jun 2029 8 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.05B
est: 1.12B (-6.8%)
|
1.30B
est: 1.22B (+6.5%)
|
1.25B
est: 1.31B (-4.8%)
|
1.22B
est: 1.39B (-12.3%)
|
1.49B
est: 1.62B (-7.8%)
|
1.65B
est: 1.74B (-5.4%)
|
1.39B
est: 1.60B (-13.2%)
|
1.40B
est: 1.60B (-13.1%)
|
1.42B
est: 1.50B (-5.6%)
|
1.47B
est: 1.52B (-3.5%)
|
1.61B
est: 1.58B (+2.3%)
|
2.04B
est: 2.01B (+1.6%)
|
1.85B
est: 1.98B (-6.6%)
|
1.63B
est: 1.65B (-0.9%)
|
1.62B
est: 1.62B (-0.2%)
|
2.00B
est: 2.04B (-2.0%)
|
1.89B
1.85B – 1.95B
-7.8% YoY
|
1.96B
1.92B – 2.01B
+3.9% YoY
|
2.03B
1.99B – 2.10B
+3.8% YoY
|
2.11B
2.07B – 2.17B
+3.7% YoY
|
| EBITDA |
147.79M
est: 70.17M (+110.6%)
|
179.98M
est: 112.44M (+60.1%)
|
182.27M
est: 125.56M (+45.2%)
|
184.89M
est: 137.85M (+34.1%)
|
214.01M
est: 169.93M (+25.9%)
|
211.94M
est: 53.27M (+297.8%)
|
243.70M
est: 184.43M (+32.1%)
|
226.30M
est: 185.39M (+22.1%)
|
209.30M
est: 151.58M (+38.1%)
|
203.30M
est: 506.96M (-59.9%)
|
261.30M
est: 134.85M (+93.8%)
|
385.64M
est: 210.01M (+83.6%)
|
291.90M
est: 213.67M (+36.6%)
|
275.20M
est: 219.39M (+25.4%)
|
202.30M
est: 222.58M (-9.1%)
|
260.20M
est: 313.85M (-17.1%)
|
290.38M
284.60M – 301.05M
-7.5% YoY
|
301.79M
295.43M – 309.49M
+3.9% YoY
|
313.15M
306.73M – 322.86M
+3.8% YoY
|
324.79M
318.13M – 334.87M
+3.7% YoY
|
| EBIT |
126.29M
est: 102.39M (+23.3%)
|
157.32M
est: 145.47M (+8.1%)
|
159.85M
est: 155.29M (+2.9%)
|
159.43M
est: 165.98M (-3.9%)
|
206.50M
est: 199.77M (+3.4%)
|
250.50M
est: 92.29M (+171.4%)
|
240.80M
est: 222.54M (+8.2%)
|
181.40M
est: 208.38M (-12.9%)
|
169.50M
est: 166.47M (+1.8%)
|
165.10M
est: 160.22M (+3.0%)
|
223.10M
est: 161.68M (+38.0%)
|
337.50M
est: 247.53M (+36.3%)
|
253.60M
est: 251.84M (+0.7%)
|
207.20M
est: 258.58M (-19.9%)
|
129.70M
est: 262.34M (-50.6%)
|
185.40M
est: 245.19M (-24.4%)
|
226.85M
222.33M – 235.19M
-7.5% YoY
|
235.77M
230.80M – 241.78M
+3.9% YoY
|
244.64M
239.62M – 252.22M
+3.8% YoY
|
253.74M
248.53M – 261.61M
+3.7% YoY
|
| Net Income |
101.48M
est: 82.35M (+23.2%)
|
131.14M
est: 116.89M (+12.2%)
|
133.04M
est: 129.41M (+2.8%)
|
124.84M
est: 138.06M (-9.6%)
|
41.80M
est: 163.52M (-74.4%)
|
142.58M
est: 46.20M (+208.6%)
|
159.10M
est: 170.10M (-6.5%)
|
147.70M
est: 161.18M (-8.4%)
|
132.52M
est: 138.29M (-4.2%)
|
111.70M
est: 491.73M (-77.3%)
|
158.70M
est: 114.81M (+38.2%)
|
246.70M
est: 178.81M (+38.0%)
|
158.70M
est: 181.92M (-12.8%)
|
148.30M
est: 148.30M (+0.0%)
|
76.50M
est: 51.01M (+50.0%)
|
101.60M
est: 66.36M (+53.1%)
|
191.12M
185.95M – 196.30M
+188.0% YoY
|
196.95M
173.74M – 220.16M
+3.0% YoY
|
222.66M
208.00M – 237.31M
+13.1% YoY
|
235.84M
229.55M – 245.35M
+5.9% YoY
|
| SGA |
313.18M
est: 256.57M (+22.1%)
|
358.89M
est: 360.67M (-0.5%)
|
359.01M
est: 354.21M (+1.4%)
|
359.93M
est: 372.65M (-3.4%)
|
458.50M
est: 471.33M (-2.7%)
|
440.70M
est: 506.74M (-13.0%)
|
319.20M
est: 415.50M (-23.2%)
|
363.40M
est: 323.36M (+12.4%)
|
389.60M
est: 340.24M (+14.5%)
|
381.20M
est: 395.58M (-3.6%)
|
416.00M
est: 391.81M (+6.2%)
|
480.10M
est: 465.32M (+3.2%)
|
412.20M
est: 473.42M (-12.9%)
|
408.90M
est: 486.09M (-15.9%)
|
429.30M
est: 493.16M (-12.9%)
|
641.10M
est: 527.21M (+21.6%)
|
487.79M
478.07M – 505.71M
-7.5% YoY
|
506.96M
496.27M – 519.89M
+3.9% YoY
|
526.03M
515.24M – 542.34M
+3.8% YoY
|
545.59M
534.40M – 562.51M
+3.7% YoY
|
| EPS |
0.76
est: 0.63 (+20.5%)
|
0.99
est: 0.98 (+1.2%)
|
1.01
est: 1.04 (-2.6%)
|
0.95
est: 0.97 (-2.2%)
|
0.29
est: 1.04 (-72.0%)
|
1.23
est: 1.20 (+2.9%)
|
1.05
est: 0.99 (+5.9%)
|
1.00
est: 1.04 (-4.2%)
|
0.92
est: 1.01 (-8.9%)
|
0.83
est: 1.07 (-22.2%)
|
1.22
est: 1.18 (+3.7%)
|
1.92
est: 1.99 (-3.4%)
|
1.19
est: 1.25 (-5.0%)
|
1.18
est: 1.15 (+3.0%)
|
0.59
est: 0.94 (-37.5%)
|
0.70
est: 1.23 (-42.9%)
|
1.31
1.27 – 1.34
+6.6% YoY
|
1.40
1.19 – 1.51
+7.1% YoY
|
1.51
1.42 – 1.62
+7.7% YoY
|
1.61
1.57 – 1.68
+7.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nathalie Ahlstrom | MD, Chief Executive Officer & Director | 3M | female |
| Rob Hughes | Chief Product & Marketing Officer | 1M | male |
| Brian Montgomery | Chief Financial Officer | 605.1K | male |
| Deanna Johnston | Chief Information Officer | — | female |
| Fred Marx | Acting CFO, VP of Corporate FP&A, Strategy and Transformation | — | male |
| John Marsden | Chief Operations & Supply Chain Officer | — | male |
| Michael Evans | Senior Director of Investor Relations and Corporate M&A | — | male |
| Philippe H. Rommel | Chief Legal Officer | — | male |
| Augusto Accorsi | Chief Commercial Officer of EMEA & APAC | — | male |
| Sean Sweeney | Chief Commercial Officer of Americas | — | male |
| Catherine Stribley | Company Secretary and VP of Corporate Governance & Social Responsibility | — | female |
| Charlotte Doll | Chief Human Resource Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANN.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
